Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:rabies_vaccine
|
| gptkbp:age |
adults and children
|
| gptkbp:approves |
gptkb:1980s
gptkb:FDA |
| gptkbp:clinical_trial |
conducted
post-exposure treatment prevention of rabies |
| gptkbp:contraindication |
severe allergic reaction
not for immunocompromised patients |
| gptkbp:developed_by |
gptkb:Sanofi_Pasteur
|
| gptkbp:dosage_form |
gptkb:item
|
| gptkbp:duration |
several years
|
| https://www.w3.org/2000/01/rdf-schema#label |
Rab Avert
|
| gptkbp:hunting_technique |
used in veterinary medicine
post-exposure prophylaxis recommended |
| gptkbp:ingredients |
inactivated rabies virus
|
| gptkbp:is_used_for |
rabies prevention
|
| gptkbp:is_vulnerable_to |
developed in the 20th century
global distribution ongoing research 2 to 8 degrees Celsius liquid formulation post-exposure prophylaxis high efficacy WHO prequalification studies on long-term immunity inactivated virus pre-exposure prophylaxis WHO recommends for high-risk groups adverse event monitoring required developed from rabies virus strains effective against rabies virus significant impact on rabies control single dose recommended |
| gptkbp:manager |
intramuscular injection
|
| gptkbp:manufacturer |
gptkb:Sanofi_Pasteur
|
| gptkbp:marketed_as |
multiple countries
|
| gptkbp:packaging |
vial
|
| gptkbp:safety_features |
generally safe
|
| gptkbp:side_effect |
headache
nausea fever pain at injection site |
| gptkbp:storage |
refrigerated
|
| gptkbp:suitable_for |
animal bites
travelers to endemic areas high-risk occupations |
| gptkbp:targets |
rabies
|
| gptkbp:treatment |
multiple doses required
|